Asthma study pulled before it started: no children enrolled
NCT ID NCT03784781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to compare certain immune cells (called ILC2) in the lungs of children with severe asthma versus children without asthma. The goal was to see if these cells are higher in asthmatic children and if they relate to other markers of airway inflammation. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Started
-
Jun 2016
- Expected to finish
-
Apr 2020
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Minors hospitalized in the department of pediatric pulmonology and allergy of Necker Hospital
- Ages
-
6 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Controls : * Minors aged 6 to 18 matched in age with severe asthmatic children * Non-asthmatic children hospitalized in the department of pediatric pulmonology and allergy in Necker Hospital * To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood collection Severe asthmatic children : * Minors aged 6 to 18 * Children hospitalized in the department of pediatric pulmonology and allergy in Necker Hospital * To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood collection * Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene Exclusion Criteria: * Children with an immune deficiency, will be excluded
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker Enfants malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle